BACKGROUND: Pancreatic cancer is one of the most lethal cancers. Despite enhanced understanding of the disease, the 5-year survival rate remains 8% due to the late stage of diagnosis and a lack of effective treatment options. Early detection of precancerous lesions, such as intraductal papillary mucinous neoplasms (IPMNs), is a strategy to prevent pancreas cancer related death. Standard qualitative imaging assessment cannot reliably distinguish between benign and malignant branch duct intraductal papillary mucinous neoplasms (BD-IPMNs). A more consistent risk prediction method is needed to inform clinical decision making such that patients with benign cysts may be spared from unnecessary surgical resection. OBJECTIVE: To assess whether a BD-IPMN malignancy risk prediction model which demonstrated strong potential on preoperative computed tomography (CT) images would show similar results on magnetic resonance imaging (MRI). METHODS: 19 pathologically proven BD-IPMN patients with preoperative contrast-enhanced CT and MRI and were included in the study. Five radiomics features were extracted from the portal-venous phase CT and MR images of the largest cyst. Associations between radiomics features extracted from CT and MR were assessed using Pearson correlations. RESULTS: Of the five radiomics features, average-weighted eccentricity (AWE) was most strongly correlated between imaging modalities in all patients (n=19, r=0.46, 95% CI=0.001-0.75, p=0.05), low-risk patients (r=0.63, 95% CI=0.09-0.88, p=0.028), and patients with a solid component or mural nodule (r=0.66, 95% CI=-0.32-0.96, p=0.15). However, when two outliers within the dataset were removed from analysis, AWE no longer correlated between MR and CT. None of the other radiomics features displayed significant correlations between the modalities. CONCLUSIONS: The CT-based risk prediction model cannot be applied to MR data suggesting that a new model should be created from MRI data alone. / 2021-06-17T00:00:00Z

付記する学位プログラム名: 充実した健康長寿社会を築く総合医療開発リーダー育成プログラム / 京都大学 / 0048 / 新制・課程博士 / 博士(医科学) / 甲第22747号 / 医科博第116号 / 新制||医科||8(附属図書館) / 京都大学大学院医学研究科医科学専攻 / (主査)教授 長船 健二, 教授 武藤 学, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21420号 / 医博第4410号 / 京都大学大学院医学研究科医学専攻 / (主査)教授 羽賀 博典, 教授 武田 俊一, 教授 坂井 義治 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Pancreatic cancer is still a dismal disease. The high mortality rate is mainly caused by the lack of highly sensitive and specific diagnostic tools, and most of the patients are diagnosed in an advanced and incurable stage. Knowledge about precursor lesions for pancreatic cancer has grown significantly over the last decade, and nowadays we know that mainly three lesions (PanIN, and IPMN, MCN) are responsible for the development of pancreatic cancer. The early detection of these lesions is still challenging but provides the chance to cure patients before they might get an invasive pancreatic carcinoma. This paper focuses on PanIN, IPMN, and MCN lesions and reviews the current level of knowledge and clinical measures.

Pancreatic cancer is still a dismal disease. The high mortality rate is mainly caused by the lack of highly sensitive and specific diagnostic tools, and most of the patients are diagnosed in an advanced and incurable stage. Knowledge about precursor lesions for pancreatic cancer has grown significantly over the last decade, and nowadays we know that mainly three lesions (PanIN, and IPMN, MCN) are responsible for the development of pancreatic cancer. The early detection of these lesions is still challenging but provides the chance to cure patients before they might get an invasive pancreatic carcinoma. This paper focuses on PanIN, IPMN, and MCN lesions and reviews the current level of knowledge and clinical measures.